assignment
Recruiting

Phase II Evaluation of Nivolumab and Nivolumab Plus Relatlimab in Locally Advanced/Metastatic Cutaneous Squamous Cell Carcinoma

Trial ID
2024-513637-20-00

Register record, history and transparency: CTIS.eu

Trial statistics

science
2
test molecules
location_city
7
research sites
public
1
country
medical_information
1
disease
person_search
7
investigators
handshake
3
vendors

Diseases & Conditions

Squamous cell carcinoma of skin

Objectives

The primary objective of this Phase II study is to determine the **Objective Response Rate (ORR)** of immunotherapy with Nivolumab (Group 1) and Nivolumab plus Relatlimab (Group 2) in patients with locally advanced or metastatic squamous cell carcinoma of the skin. This is assessed using the Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) per site assessment, with a time frame extending from the first dose up to five years. The ORR is a critical measure of the efficacy of the treatment, indicating the proportion of patients who experience a predefined reduction in tumor size, which is clinically relevant for evaluating the potential benefits of the therapy.

Secondary objectives include: - **Disease Control Rate (DCR)** using RECIST 1.1, measured from the first dose to the date of first documented tumor progression or death, up to five years. - **Duration of Response (DOR)** in patients achieving partial response or better, from the time of documented response to progression or death, up to five years. - **Progression-Free Survival (PFS)**, from the first dose to progression or death, up to five years. - **Overall Survival (OS)**, from the first dose to death from any cause, up to five years. - Evaluation of ORR, DCR, DOR, PFS, and OS in patients with PD-L1-positive tumor expression and/or positive LAG-3 expression. - Assessment of the safety and toxicity of Nivolumab plus Relatlimab.

Participants

The clinical trial involves participants diagnosed with **locally advanced or metastatic squamous cell carcinoma of the skin**. The study population includes both men and women aged 18 years and older, with a life expectancy of at least 12 weeks and an Eastern Cooperative Oncology Group (ECOG) Performance status of 0-2. Participants must have histologically or cytologically documented stage III/IV disease that is incurable, and archival tumor tissue must be available for evaluation of PD-L1 and LAG-3 expression. The trial includes individuals with measurable disease based on Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1). The sponsor has not provided the total number of participants. The selection criteria require participants to have completed prior radiotherapy at least two weeks before study drug administration and any prior systemic antibiotic treatment at least 30 days before stool sample collection. Both male and female subjects are included, and the trial considers vulnerable populations. The sponsor has not provided specific information regarding lifestyle considerations such as diet or physical activity.

Plans and Procedures

The clinical trial is designed to evaluate the **Objective Response Rate (ORR)** of immunotherapy using **nivolumab** alone and in combination with **relatlimab** in patients with locally advanced or metastatic squamous cell carcinoma of the skin. This is a Phase II, randomized, double-blind, controlled study. The trial will span from the estimated recruitment start date in October 2016 to the estimated end date in December 2029, with a maximum treatment period of 101 weeks for participants.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to confirm eligibility based on criteria such as age, documented disease status, and laboratory values. The screening visit will also involve the collection of archival tumor tissue for evaluation of PD-L1 and LAG-3 expression. Following successful screening, participants will be randomized into one of two groups: Group 1 receiving nivolumab alone, and Group 2 receiving nivolumab plus relatlimab. Both treatments will be administered via intravenous infusion.

Subsequent follow-up visits will be scheduled to monitor the participants' response to treatment, assess disease progression, and evaluate safety and toxicity. These visits will include assessments based on the Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1). The primary endpoint is the ORR, while secondary endpoints include Disease Control Rate (DCR), Duration of Response (DOR), Progression-Free Survival (PFS), and Overall Survival (OS). The trial will also assess the safety and toxicity of the combination therapy.

The expected length of participant involvement is up to five years, depending on individual response and disease progression. Conditions that may lead to early termination from the study include significant adverse events, disease progression, or withdrawal of consent. The trial aims to provide valuable insights into the efficacy and safety of nivolumab and relatlimab in treating this specific type of skin cancer.

Treatment

The clinical trial involves two treatment groups, each receiving a distinct experimental medication. The first group is administered **OPDIVO**, a **concentrate for solution for infusion** containing the active substance **nivolumab**. This medication is provided in a concentration of 10 mg/mL and is intended for **intravenous use**. The maximum daily dose for OPDIVO is 240 mg, with a total maximum dose of 240 mg over the treatment period. The treatment duration is set for a maximum of 101 days. Nivolumab is a protein-based therapeutic agent, specifically a human monoclonal antibody (IgG4-S228P), and is manufactured by Bristol-Myers Squibb Pharma EEIG.

The second group receives a combination therapy of **Nivolumab/Relatlimab**, also formulated as a **solution for infusion**. This combination includes the active substances **nivolumab** and **relatlimab**, both of which are protein-based agents. The maximum daily dose for this combination therapy is 480 mg, with a total maximum dose of 480 mg over the treatment period, which is also set for a maximum of 101 days. The administration route is **intravenous use**. Relatlimab is a fully human LAG-3-specific antibody, and the combination product is developed by Bristol-Myers Squibb International Corporation. The dosing schedule and participant compliance are monitored throughout the trial to ensure adherence to the protocol.

Efficacy

The efficacy of the clinical trial will be assessed primarily through the **Objective Response Rate (ORR)**, which will be determined using the Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) per site assessment. This primary endpoint will evaluate the response to immunotherapy with Nivolumab (Group 1) and Nivolumab plus Relatlimab (Group 2) in patients with locally advanced or metastatic squamous cell carcinoma of the skin. The time frame for this assessment extends from the first dose up to five years.

Secondary endpoints include the **Disease Control Rate (DCR)**, **Duration of Response (DOR)**, **Progression-Free Survival (PFS)**, and **Overall Survival (OS)**. These will also be measured using RECIST 1.1 criteria. The DCR will be assessed from the first dose to the date of first documented tumor progression or death, whichever occurs first, up to five years. The DOR will be evaluated from the date of documented partial response or better to the date of first documented tumor progression or death, up to five years. PFS will be measured from the first dose to the date of first documented tumor progression or death, up to five years. OS will be assessed from the first dose to the date of death due to any cause, up to five years.

Additional analyses will be conducted for patients with PD-L1-positive tumor expression and/or positive LAG-3 expression, evaluating ORR, DCR, DOR, PFS, and OS. Safety and toxicity of the combination therapy with Nivolumab plus Relatlimab (Group 2) will also be monitored throughout the trial duration.

Inclusion and Exclusion Criteria

check_circle

Inclusion Criteria

  • Men and women, 18 years of age and older on day of signing written informed consent
  • Histologically or cytologically documented locally-advanced and/or metastatic squamous cell carcinoma of the skin (stage III/IV AJCC 2010) that is incurable
  • Archival tumor tissue available for evaluation of PD-L1 and LAG-3 expression
  • Measurable disease based on Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
  • Life expectancy of at least 12 weeks
  • Eastern Cooperative Oncology Group (ECOG) Performance status of 0-2
  • Screening laboratory values must meet the following criteria and should be obtained within 14 days prior to registration: o WBC ≥ 2000/μl o Neutrophils ≥ 1500/μL o Platelets ≥ 100 x103/μL o Hemoglobin > 9.0 g/dL o Serum creatinine ≤ 1.5 x ULN or creatinine clearance (CrCl) ≥ 40 mL/min (if using the Cockcroft-Gault formula below): Female CrCl = (140 - age in years) x weight in kg x 0.85 72 x serum creatinine in mg/dL Male CrCl = (140- age in years) x weight in kg x 1.00 72 x serum creatinine in mg/dL o AST/ALT ≤ 3 x ULN o Total Bilirubin ≤ 1.5 x ULN (except subjects with Gilbert Syndrome, who can have total bilirubin < 3.0 mg/dL) o Negative pregnancy test and effective contraception (Pearl-Index <1) for women of childbearing potential (WOCBP) if the risk of conception exists
  • Prior radiotherapy must have been completed at least 2 weeks prior to study drug administration
  • Prior systemic antibiotic treatment must have been completed at least 30 days prior to stool sample collection
cancel

Exclusion Criteria

  • Patient is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
  • Prior therapy with CTLA-4, PD-1 or LAG-3 antibodies
  • History of myocarditis, regardless of etiology
  • Troponin T (TnT) or I (TnI) >2x institutional upper limit of normal (ULN). In case of Troponin between 2-3x ULN at baseline, repeated measurement after 48-72 hours is recommend. If the patient continues to be asymtomatic and no relevant dynamic change of the TnT or TnI values occurs within this time frame (further Troponin increase >1,5x of the individual baseline TnT or TnI), the patient can be included at the discretion of the investigator and/or consultation of cardiologist. A further increase in TnT or TnI as described would be exclusionary and should prompt cardiologic consultation. Depending on the further course and the cardiologic diagnosis re-screening may be considered. Participants with TnT or TnI levels between >1x to 2x ULN will be permitted if repeat levels within 24 hours are <= 1x ULN. If TnT or TnI levels are between >1x to 2x ULN within 24 hous, the participant may undergo a cardiac evaluation and be considered for treatment, based on a favorable benefit/risk assessment by the Investigator. When repeat levels within 24 hours are not available, a repeat test should be conducted as soon as possible. If TnT or TnI repeat levels beyond 24 hours are <2x ULN, the participant may undergo a cardiac evaluation and be considered for treatment, based on a favorable benefit/risk assessment by the Investigator.
  • A condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease
  • Known active central nervous system (CNS) metastases and/or carcinomatous meningitis
  • Known additional malignancy that is progressing or requires active treatment. Patients with chronic lymphocytic leukemia that is stable under active therapy are eligible for inclusion
  • An active, known or suspected autoimmune disease. Subjects are permitted to enroll if they have vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger
  • Patients with serious intercurrent illness, requiring hospitalization
  • Other serious illnesses, e.g. serious infections requiring antibiotics or hospitalization
  • Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
  • Pregnancy (absence to be confirmed by ß-HCG urinary test, minimum sensitivity 25 IU/L or equivalent units of HCG)) or lactation period
  • Women of childbearing potential (WOCBP): Refusal or inability to use effective means of contraception (Pearl-Index <1)
  • History of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS)
  • Positive test for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic infection
  • History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the best interest of the patient to participate, in the opinion of the treating Investigator
  • Known hypersensitivity reaction to any of the components of study treatment

Trial Status by Country

Country Status Start of Recruitment Planned Patients
Austria AustriaRecruiting01 Oct 201661

Sites & Investigators

Investigational Products

Details about the medicinal products being studied in this clinical trial.

Product Name Role in Trial Formulation Administration Max Daily Dose Treatment Duration EU MP Number
OPDIVO 10 mg/mL concentrate for solution for infusion.
TestCONCENTRATE FOR SOLUTION FOR INFUSIONINTRAVENOUS USE240101PRD2941375
Nivolumab/Relatlimab
TestSOLUTION FOR INFUSIONINTRAVENOUS USE480101PRD9854659

Conditions Studied in This Trial

Interventions Studied in This Trial

vaccines
Nivolumab
216 trials

Also investigated for

Non-small cell lung cancer 26Malignant melanoma 23Neoplasm 17Renal cell carcinoma 14
vaccines
Relatlimab
28 trials

Also investigated for

Malignant melanoma 5Neoplasm malignant 4Hepatocellular carcinoma 3Neoplasm 3